Clinical Trial Update: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy [Phase 3]

View source ↗

Summary

A Phase 3 trial of SHR3680 in high-risk localized or locally advanced prostate cancer patients eligible for radical prostatectomy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• SHR3680

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Phase 3 | Status: TERMINATED